Ancestry and other genetic associations with plasma PCSK9 response to simvastatin.

ABSTRACT:

Objective

Statins stimulate transcription of proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of the low-density lipoprotein receptor, thus blunting the cholesterol-lowering effects of statin treatment. Although there is interindividual variation in PCSK9 statin response, little is known about ancestral and other genetic factors that could contribute to this variation.

Methods

We measured plasma PCSK9 levels before and after 6 weeks of treatment with 40 mg/day simvastatin in 901 participants of the Cholesterol and Pharmacogenetics clinical trial and tested phenotypic and genetic factors for correlation with PCSK9 statin response.

Results

Statin-induced changes in plasma low-density lipoprotein cholesterol, total cholesterol, and apolipoprote

SUBMITTER: Theusch E 

PROVIDER: S-EPMC4159722 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature